Health-E Law Podcast, Episode 24 | ViVE 2026: AI and the Future of Healthcare
Taking The Pulse, A Health Care and Life Sciences Video Podcast | Episode 272: Humanism and Transplant Care with Dr. Joseph Scalea of MUSC
AI in Healthcare: Five Healthcare AI Stories You Need to Know This Week - April 3, 2026
How to Stay HIPAA Compliant When Using Health Care Analytics
PBM Reform 2026: What Recent Legislation Means for the Industry
McDonald Hopkins Legal Diagnosis Podcast, Episode 8: Stark Law
Taking The Pulse, A Health Care and Life Sciences Video Podcast | Episode 271: Advancing Neurotrauma Treatments with Ken Webb of NeuroHope Therapeutics
AI in Healthcare: Five Healthcare AI Stories You Need to Know This Week – March 27, 2026
Health-e Law Podcast, Episode 23 | The Future of Brain Tech With Dr. Newton Howard
Hospice Insights Podcast - What’s New? CMS Provisional Period of Enhanced Oversight Application to “New” Hospices
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 270: Building a Future-Ready Workforce in Life Sciences with Daniel Grove of Lonza
State AGs in Action: Health Care Enforcement in 2026 – Speaking of Litigation Video Podcast
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 269: Investing in Distributed Healthcare with Gordon Maner of Frontline Healthcare Partners
Podcast - States Propose New Laws Affecting Healthcare Real Estate Investors and Owners
Hospice Insights Podcast - PPEO Playbook: The High-Stakes Game Hospices Can’t Afford to Lose
Podcast - Assessing the State of Healthcare Restructurings
Leaders in Law: Life Sciences and Technology Transactions with Jekkie Kim
Health-e Law Podcast, Episode 22 | J.P. Morgan Healthcare 2026 and Beyond: Regulation, Technology and the Future of Health Equity
Podcast — Spotlight on US State Healthcare Transaction Review Laws
Taking the Pulse: A Health Care and Life Sciences Video Podcast | Episode 268: Inside South Carolina’s Life Sciences Growth with James Chappell of SCbio
Massachusetts AG Andrea Joy Campbell announced draft regulations defining specific unfair or deceptive acts within assisted living residences under the state’s consumer protection law. Among other requirements, the draft...more
On April 2, 2026, President Trump issued a proclamation under section 232 tariff authority imposing sweeping new tariffs on patented pharmaceutical products and ingredients imported into the U.S., with rates reaching up to...more
The Food and Drug Administration (FDA)’s FY 2027 budget proposal, which is the first fully developed under Commissioner Marty Makary’s tenure, includes a wide-ranging collection of legislative proposals that aim to expand the...more
While federal and state legislators contemplate the next wave of PBM and drug pricing reform, legislatures in Virginia and Ohio have already sent significant legislation addressing prescription drug pricing and pharmacy...more
While Section 232 tariffs have so far been largely a metals-and-autos story, pharma has now officially joined the narrative....more
Offering discounts on pricing of medical products is often proposed as an advantageous business strategy in the health care industry. While offering discounts is a longstanding and common practice, if structured improperly,...more
On April 1, 2026, the Centers for Medicare & Medicaid Services (CMS), through the CMS Innovation Center (CMMI), officially launched a new pilot program which allows participants in specific CMS programs to offer eligible hemp...more
On April 7, 2026, the Department of Justice (“DOJ”) announced plans to consolidate and realign resources to staff the National Fraud Enforcement Division (the “Fraud Division”) that was created by President Trump in January...more
The 2026 White Collar Year in Preview ebook provides a comprehensive analysis of anticipated enforcement trends and legal developments across key areas of white collar law. As the federal government continues to advance its...more
Key Takeaways - Florida is formalizing memory care regulation for assisted living facilities (“ALFs”). A new specialty license for memory care services, administered by the Agency for Health Care Administration (“AHCA”), will...more
On April 2, 2026, President Donald Trump issued a proclamation titled “Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States” (the Proclamation) under Section 232 of the Trade Expansion...more
This regular publication by DLA Piper lawyers focuses on helping clients navigate the ever-changing business, legal, and regulatory landscape....more
Following the Council of the European Union and the European Parliament reaching an agreement in the trilogue negotiations on the so-called Pharma Package in December 2025, the texts of the provisional agreement (comprising a...more
Deferred consideration is frequently used in physician practice sales to bridge valuation gaps and allocate post-closing risk (and upside) between buyers and sellers. Commonly structured as earnouts, deferred consideration...more
In February 2026, the Department of Health and Human Services, Office of Inspector General (HHS-OIG) issued its highly anticipated Industry Compliance Program Guidance for Medicare Advantage (MA ICPG), the first such...more
On March 31, 2026, the Food and Drug Administration (FDA) published a notice in the Federal Register requesting information and public comment (RFI) on the use of digital health technologies (DHTs) in clinical investigations...more
FDA released its FY 2027 congressional justification last week. The $7.2 billion topline is less interesting than what's underneath it—the budget translates this administration's policy signals into concrete funding and...more
Recent changes to the Medicare Diabetes Prevention Program (“MDPP”) are in sync with recent Centers for Medicare and Medicaid Services (“CMS”) initiatives to utilize technology to make healthcare services more accessible and...more
On March 30, 2026, Teva Pharmaceutical Industries Ltd. (“Teva”) announced that the U.S. Food and Drug Administration (“FDA”) has approved its denosumab biosimilar, PONLIMSI™ (denosumab-adet). ...more
The Centers for Medicare & Medicaid Services (CMS) has issued its Advance Notice and related rulemaking for the Medicare Advantage (MA) and Part D programs for plan year 2027. ...more
The CMS Innovation Center has released the request for applications (RFA) for the Long-term Enhanced ACO Design (LEAD) model, a new 10-year accountable care initiative that will begin in 2027....more
Consumer demand for GLP‑1 drugs such as Ozempic and Zepbound continues to surge, fueling rapid growth in the market for GLP-1 drugs and compounded GLP-1 products, as well as supplements that are marketed to have similar...more
The next wave of healthcare dealmaking will be won by tech-enabled platforms driving value and efficiency at scale. At McDermott Will and Schulte’s HPE Miami 2026 conference, discussions among investors, operators, regulatory...more
Find the week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we comb through the dockets of more than 50 340B cases to provide you with a quick summary...more
On March 11, 2026, the Office of Inspector General (OIG) issued Advisory Opinion No. 26-05, concluding that it would not impose sanctions on a medical device company (Requestor) that proposes to subsidize Medicare...more
